{"id":60175,"date":"2025-07-10T20:13:40","date_gmt":"2025-07-10T20:13:40","guid":{"rendered":"https:\/\/cdhf.staging.not4prod.com\/lere-evolutive-des-biosimilaires\/"},"modified":"2025-07-11T13:15:58","modified_gmt":"2025-07-11T13:15:58","slug":"lere-evolutive-des-biosimilaires","status":"publish","type":"post","link":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/","title":{"rendered":"L&#8217;\u00e8re \u00e9volutive des biosimilaires"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><em>Examin\u00e9 par le Dr Frank Hoentjen, MD PhD Professeur de m\u00e9decine Directeur du Centre des maladies inflammatoires de l&#8217;intestin<\/em><\/p>\n\n<p class=\"wp-block-paragraph\">Ces derni\u00e8res ann\u00e9es, la disponibilit\u00e9 des biosimilaires a jou\u00e9 un r\u00f4le important dans l&#8217;am\u00e9lioration de l&#8217;acc\u00e8s aux traitements biologiques, notamment pour les maladies inflammatoires telles que la <a href=\"https:\/\/cdhf.ca\/en\/digestive-conditions\/ibd-crohns-disease\/\">maladie de Crohn<\/a>, la <a href=\"https:\/\/cdhf.ca\/en\/digestive-conditions\/ibd-ulcerative-colitis\/\">colite ulc\u00e9reuse<\/a> et la polyarthrite rhumato\u00efde.  <\/p>\n\n<p class=\"wp-block-paragraph\">Les biosimilaires sont des m\u00e9dicaments biologiques tr\u00e8s similaires au produit biologique d&#8217;origine en termes de structure, de fonction, d&#8217;efficacit\u00e9 et de s\u00e9curit\u00e9, m\u00eame s&#8217;ils peuvent pr\u00e9senter de l\u00e9g\u00e8res diff\u00e9rences en raison de la complexit\u00e9 inh\u00e9rente aux produits biologiques.<\/p>\n\n<p class=\"wp-block-paragraph\">Les organismes de r\u00e9glementation tels que Sant\u00e9 Canada, la Food and Drug Administration (FDA) des \u00c9tats-Unis et l&#8217;Agence europ\u00e9enne des m\u00e9dicaments (EMA) exigent que les biosimilaires d\u00e9montrent leur similarit\u00e9 avec le produit biologique de r\u00e9f\u00e9rence en termes d&#8217;efficacit\u00e9 clinique, de s\u00e9curit\u00e9 et d&#8217;immunog\u00e9nicit\u00e9 (capacit\u00e9 \u00e0 provoquer une r\u00e9ponse immunitaire).<\/p>\n\n<h2 class=\"wp-block-heading\">Biosimilaires et MICI<\/h2>\n\n<p class=\"wp-block-paragraph\">En tant que versions \u00e9quivalentes et moins co\u00fbteuses des m\u00e9dicaments biologiques d&#8217;origine, les biosimilaires offrent de nouvelles approches th\u00e9rapeutiques dans le traitement des MICI. Les co\u00fbts r\u00e9duits des biosimilaires rendent les traitements des MICI plus accessibles \u00e0 un plus grand nombre de patients, en particulier ceux qui peuvent \u00eatre limit\u00e9s par les prix \u00e9lev\u00e9s des m\u00e9dicaments. Cette accessibilit\u00e9 accrue et am\u00e9lior\u00e9e aux th\u00e9rapies biologiques contribue \u00e0 la viabilit\u00e9 \u00e0 long terme des syst\u00e8mes de sant\u00e9.    <\/p>\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" data-src=\"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-3-1024x461.webp\" alt=\"infirmi&#xE8;re dans une clinique de produits biosimilaires\" class=\"wp-image-60170 lazyload\"\/><noscript><img decoding=\"async\" src=\"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-3-1024x461.webp\" alt=\"infirmi&#xE8;re dans une clinique de produits biosimilaires\" class=\"wp-image-60170 lazyload\"\/><\/noscript><\/figure>\n\n<h2 class=\"wp-block-heading\">Comprendre le passage d&#8217;un biosimilaire \u00e0 un autre<\/h2>\n\n<p class=\"wp-block-paragraph\">Avec l&#8217;augmentation du nombre de biosimilaires disponibles, les patients sont confront\u00e9s \u00e0 la situation de passer d&#8217;un biosimilaire \u00e0 un autre. Les changements multiples (transitions) entre biosimilaires d&#8217;un m\u00eame produit biologique d&#8217;origine sont aujourd&#8217;hui une r\u00e9alit\u00e9, et ils devraient devenir plus courants \u00e0 l&#8217;avenir, \u00e0 mesure que de nouveaux biosimilaires arriveront sur le march\u00e9. Le passage d&#8217;un biosimilaire \u00e0 un autre est g\u00e9n\u00e9ralement motiv\u00e9 par des raisons d&#8217;accessibilit\u00e9 financi\u00e8re, par des exigences de formulaire ou par le d\u00e9m\u00e9nagement ou le voyage du patient.    <\/p>\n\n<p class=\"wp-block-paragraph\">Les donn\u00e9es cliniques actuelles sugg\u00e8rent que le passage d&#8217;un biosimilaire \u00e0 un autre est une pratique clinique s\u00fbre et efficace, sans r\u00e9duction de l&#8217;efficacit\u00e9 ni augmentation des effets ind\u00e9sirables. Au<sup>31<\/sup> d\u00e9cembre 2023, 31 \u00e9tudes d&#8217;observation ont \u00e9t\u00e9 publi\u00e9es, incluant un total de 6 081 patients ayant subi un changement d&#8217;un biosimilaire \u00e0 un autre biosimilaire du m\u00eame produit biologique d&#8217;origine. La plupart des \u00e9tudes ont \u00e9valu\u00e9 l&#8217;infliximab.  <\/p>\n\n<p class=\"wp-block-paragraph\">\u00c0 la suite de l&#8217;examen des donn\u00e9es cliniques actuelles, l&#8217;EMA et la FDA ont toutes deux publi\u00e9 des d\u00e9clarations favorables au passage d&#8217;un biosimilaire \u00e0 un autre biosimilaire du m\u00eame produit biologique d&#8217;origine, et ont indiqu\u00e9 qu&#8217;aucune diff\u00e9rence n&#8217;\u00e9tait observ\u00e9e en termes d&#8217;efficacit\u00e9, de s\u00e9curit\u00e9 ou d&#8217;immunog\u00e9nicit\u00e9 \u00e0 la suite d&#8217;un ou de plusieurs passages d&#8217;un biosimilaire \u00e0 un autre.<\/p>\n\n<p class=\"wp-block-paragraph\">La disponibilit\u00e9 de ces nouvelles donn\u00e9es d&#8217;efficacit\u00e9 et de s\u00e9curit\u00e9 ainsi que les d\u00e9clarations favorables de l&#8217;EMA et de la FDA confirment \u00e0 nouveau que le passage d&#8217;un biosimilaire \u00e0 un autre est une pratique clinique efficace, qui ne pose pas de nouveaux probl\u00e8mes de s\u00e9curit\u00e9.<\/p>\n\n<h2 class=\"wp-block-heading\"><strong>Consid\u00e9rations pour le patient lors du changement de biosimilaire<\/strong><\/h2>\n\n<p class=\"wp-block-paragraph\">Dans certains cas, l&#8217;\u00e9change est une option th\u00e9rapeutique n\u00e9cessaire. Cependant, chaque changement s&#8217;accompagne de questions, d&#8217;inqui\u00e9tudes et d&#8217;incertitudes. Les patients doivent en discuter avec leur m\u00e9decin pour bien comprendre les avantages et\/ou les risques possibles. Ensemble, ils peuvent d\u00e9cider si le changement de traitement est appropri\u00e9 \u00e0 l&#8217;\u00e9tat actuel du patient et \u00e0 sa situation.   <\/p>\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" data-src=\"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-2-1-1024x461.webp\" alt=\"infirmi&#xE8;re parlant du passage d'un biosimilaire &#xE0; un autre\" class=\"wp-image-60168 lazyload\"\/><noscript><img decoding=\"async\" src=\"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-2-1-1024x461.webp\" alt=\"infirmi&#xE8;re parlant du passage d'un biosimilaire &#xE0; un autre\" class=\"wp-image-60168 lazyload\"\/><\/noscript><\/figure>\n\n<p class=\"wp-block-paragraph\">Actuellement, 25 produits biologiques ou biosimilaires sont disponibles au Canada pour le traitement des MICI (maladie de Crohn et colite ulc\u00e9reuse).<\/p>\n\n<h2 class=\"wp-block-heading\"><strong>Informations importantes pour les patients sous INFLECTRA :<\/strong> <\/h2>\n\n<ul class=\"wp-block-list\">\n<li>\u00c0 partir de septembre 2025, Inflectra ne sera plus disponible chez Pfizer. Il sera remplac\u00e9 par <strong>Ixifi<\/strong>, la derni\u00e8re version d&#8217;Infliximab,   <\/li>\n\n\n\n<li>Si vous prenez actuellement Inflectra, vous pouvez \u00eatre assur\u00e9 que vous pouvez passer en toute s\u00e9curit\u00e9 \u00e0 Ixifi et continuer \u00e0 suivre votre programme de soutien aux patients.<\/li>\n\n\n\n<li>L&#8217;Inflectra est toujours disponible pour les patients qui souhaitent continuer \u00e0 le prendre. Cependant, Celltrion le propose d\u00e9sormais sous le nom de <strong>Remdantry<\/strong>. <\/li>\n<\/ul>\n\n<p class=\"wp-block-paragraph\">Pour consulter les listes actualis\u00e9es de produits biosimilaires, rendez-vous sur <a href=\"https:\/\/health-products.canada.ca\/dpd-bdpp\/dispatch-repartition#results\">la base de donn\u00e9es des produits de Sant\u00e9 Canada.<\/a><\/p>\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Produit biologique d&#8217;origine et ses biosimilaires<\/strong><\/td><td><strong>Maladie de Crohn adulte\/enfant (A\/P)<\/strong><\/td><td><strong>Colite ulc\u00e9reuse<br\/>Adulte\/enfant (A\/P)<\/strong><\/td><\/tr><tr><td><strong>Adalimumab<\/strong><strong><\/strong><\/td><td>\u00a0<\/td><td>\u00a0<\/td><\/tr><tr><td>Humira\u00ae &#8211; Injection<\/td><td>A\/P<\/td><td>A\/P<\/td><\/tr><tr><td>Abrilada\u00ae &#8211; Injection<\/td><td>A\/P<\/td><td>A\/P<\/td><\/tr><tr><td>Amgevita\u00ae &#8211; Injection<\/td><td>A\/P<\/td><td>A\/P<\/td><\/tr><tr><td>Hadlima\u00ae &#8211; Injection<\/td><td>A\/P<\/td><td>P<\/td><\/tr><tr><td>Hyrimoz\u00ae &#8211; Injection<\/td><td>A\/P<\/td><td>A\/P<\/td><\/tr><tr><td>Hulio\u00ae &#8211; Injection<\/td><td>A\/P<\/td><td>A\/P<\/td><\/tr><tr><td>Idacio\u00ae &#8211; Injection<\/td><td>A\/P<\/td><td>A<\/td><\/tr><tr><td>Simlandi\u2122 &#8211; Injection<\/td><td>A\/P<\/td><td>A<\/td><\/tr><tr><td>Yuflyma\u2122 &#8211; Injection<\/td><td>A\/P<\/td><td>A<\/td><\/tr><tr><td>\u00a0<\/td><td>\u00a0<\/td><td>\u00a0<\/td><\/tr><tr><td><strong>Infliximab<\/strong><\/td><td>\u00a0<\/td><td>\u00a0<\/td><\/tr><tr><td>Remicade\u00ae &#8211; Perfusion<\/td><td>A\/P<\/td><td>A\/P<\/td><\/tr><tr><td>Avsola\u2122 &#8211; Infusion<\/td><td>A\/P<\/td><td>A\/P<\/td><\/tr><tr><td>Ixifi\u00ae &#8211; Infusion<\/td><td>A\/P<\/td><td>A\/P<\/td><\/tr><tr><td>Omvyence\u2122 &#8211; Infusion<\/td><td>A\/P<\/td><td>A\/P<\/td><\/tr><tr><td>Remdantry\u2122 &#8211; Infusion<\/td><td>A\/P<\/td><td>A\/P<\/td><\/tr><tr><td>Remsima\u2122 SC &#8211; Injection<\/td><td>A\/P<\/td><td>A<\/td><\/tr><tr><td>Renflexis\u2122 &#8211; Perfusion<\/td><td>A\/P<\/td><td>A\/P<\/td><\/tr><tr><td>\u00a0<\/td><td>\u00a0<\/td><td>\u00a0<\/td><\/tr><tr><td><strong>Golimumab<\/strong><\/td><td>\u00a0<\/td><td>\u00a0<\/td><\/tr><tr><td>Simponi\u00ae &#8211; Injection<\/td><td>\u00a0<\/td><td>A<\/td><\/tr><tr><td>\u00a0<\/td><td>\u00a0<\/td><td>\u00a0<\/td><\/tr><tr><td><strong>Mirikizumab<\/strong><\/td><td>\u00a0<\/td><td>\u00a0<\/td><\/tr><tr><td>Omvoh\u2122 &#8211; Injection\/Infusion<\/td><td>\u00a0<\/td><td>A<\/td><\/tr><tr><td>\u00a0<\/td><td>\u00a0<\/td><td>\u00a0<\/td><\/tr><tr><td><strong>Risankizumab<\/strong><\/td><td>\u00a0<\/td><td>\u00a0<\/td><\/tr><tr><td>Skyrizi\u00ae &#8211; Injection\/Infusion<\/td><td>A<\/td><td>\u00a0<\/td><\/tr><tr><td>\u00a0<\/td><td>\u00a0<\/td><td>\u00a0<\/td><\/tr><tr><td><strong>Ustekinumab<\/strong><\/td><td>\u00a0<\/td><td>\u00a0<\/td><\/tr><tr><td>Finlius\u00ae (anciennement Stelara\u00ae) &#8211; Injection\/perfusion<\/td><td>A<\/td><td>A<\/td><\/tr><tr><td>Jamteki\u00ae &#8211; Injection\/Infusion<\/td><td>A<\/td><td>A<\/td><\/tr><tr><td>Otulfi\u00ae &#8211; Injection\/perfusion<\/td><td>A<\/td><td>A<\/td><\/tr><tr><td>Steqeyma\u00ae &#8211; Injection\/Infusion<\/td><td>A<\/td><td>A<\/td><\/tr><tr><td>Wezlana\u2122 &#8211; Injection\/Infusion<\/td><td>A<\/td><td>A<\/td><\/tr><tr><td>\u00a0<\/td><td>\u00a0<\/td><td>\u00a0<\/td><\/tr><tr><td><strong>Vedolizumab<\/strong><\/td><td>\u00a0<\/td><td>\u00a0<\/td><\/tr><tr><td>Entyvio\u00ae &#8211; Injection\/perfusion<\/td><td>A<\/td><td>A<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<p class=\"wp-block-paragraph\"><strong>Indications p\u00e9diatriques :<\/strong><strong><\/strong><\/p>\n\n<p class=\"wp-block-paragraph\"><em>Les indications pour les enfants varient en fonction de l&#8217;\u00e2ge, du poids, de la gravit\u00e9 de la maladie et de l&#8217;\u00e9chec des autres traitements conventionnels et\/ou biologiques. Vos discussions avec votre m\u00e9decin permettront d&#8217;\u00e9tablir le traitement le plus appropri\u00e9. <\/em><\/p>\n\n<p class=\"wp-block-paragraph\"><em>Cette liste a \u00e9t\u00e9 cr\u00e9\u00e9e en mai 2025 et peut faire l&#8217;objet de modifications.<\/em><\/p>\n\n<h2 class=\"wp-block-heading\">Le bilan<\/h2>\n\n<p class=\"wp-block-paragraph\">Bien que les biosimilaires offrent des avantages significatifs, notamment des \u00e9conomies et un meilleur acc\u00e8s aux traitements, le passage d&#8217;un biosimilaire \u00e0 un autre est une d\u00e9cision complexe qui n\u00e9cessite une \u00e9valuation minutieuse des facteurs cliniques, financiers et r\u00e9glementaires. Le suivi continu et la communication entre les prestataires de soins de sant\u00e9 et les patients sont essentiels pour une transition r\u00e9ussie entre les biosimilaires. \u00c0 l&#8217;avenir, des donn\u00e9es concr\u00e8tes pourraient permettre de mieux comprendre le passage d&#8217;un biosimilaire \u00e0 un autre au fur et \u00e0 mesure de l&#8217;\u00e9volution de la technologie biosimilaire, ce qui permettrait de guider les d\u00e9cisions cliniques pour obtenir des r\u00e9sultats optimaux pour les patients \u00e0 l&#8217;\u00e8re des biosimilaires.  <\/p>\n<div class=\"gradient-divider\"><\/div><div class=\"sponsor-block\"><p><p><span style=\"color:rgb(31,31,31);\"><strong>This article was made possible due to an unrestricted educational grant from Pfizer Canada.<\/strong><\/span><\/p><\/p><div class=\"sponsor-details\"><\/div><\/div>\n<p class=\"wp-block-paragraph\"><strong>R\u00e9f\u00e9rences :<\/strong><\/p>\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38520607\/\"><strong>Des donn\u00e9es suppl\u00e9mentaires sur des populations de patients \u00e9largies et de nouvelles indications soutiennent la pratique du passage d&#8217;un biosimilaire \u00e0 un autre <\/strong>Hillel P Cohen<\/a><strong><u><\/u><\/strong><\/p>\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.centerforbiosimilars.com\/view\/new-evidence-confirms-safe-biosimilar-to-biosimilar-switching\"><strong>AJMC &#8211; Le Centre des biosimilaires<\/strong><\/a><\/p>\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"https:\/\/www.centerforbiosimilars.com\/view\/new-evidence-confirms-safe-biosimilar-to-biosimilar-switching\">De nouvelles donn\u00e9es confirment la s\u00e9curit\u00e9 du passage d&#8217;un biosimilaire \u00e0 un autre 28 mai 2024<\/a><\/strong><strong><u><\/u><\/strong><\/p>\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9485085\/#:~:text=Overall%2C%20the%20authors%20concluded%20that,(anti%2DTNF)%20treatment.\"><strong>Passage d&#8217;un biosimilaire \u00e0 un autre biosimilaire du m\u00eame produit de r\u00e9f\u00e9rence : Une revue syst\u00e9matique des \u00e9tudes <\/strong>Hillel P Cohen  <\/a><strong><u><\/u><\/strong><\/p>\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34223654\/#:~:text=or%20second%20switch-,An%20observational%20study%20of%20switching%20infliximab%20biosimilar:%20no%20adverse%20impact,Epub%202021%20Jul%205.\"><strong>\u00c9tude d&#8217;observation du changement de biosimilaire de l&#8217;infliximab : pas d&#8217;impact n\u00e9gatif sur le contr\u00f4le de la maladie inflammatoire de l&#8217;intestin ou sur les niveaux de m\u00e9dicaments lors du premier ou du deuxi\u00e8me changement <\/strong>Raphael P Luber<\/a><strong><u><\/u><\/strong><\/p>\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2324123#d1e158\">Examen de l&#8217;impact du passage d&#8217;un biosimilaire \u00e0 un autre sur l&#8217;efficacit\u00e9 et la s\u00e9curit\u00e9 Anan S. Jarab<\/a><\/strong><strong><u><\/u><\/strong><\/p>\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/biosimilar-biologic-drugs.html\"><strong>Sant\u00e9 Canada<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Examin\u00e9 par le Dr Frank Hoentjen, MD PhD Professeur de m\u00e9decine Directeur du Centre des maladies inflammatoires de l&#8217;intestin Ces derni\u00e8res ann\u00e9es, la disponibilit\u00e9 des biosimilaires a jou\u00e9 un r\u00f4le important dans l&#8217;am\u00e9lioration de l&#8217;acc\u00e8s aux traitements biologiques, notamment pour les maladies inflammatoires telles que la maladie de Crohn, la colite ulc\u00e9reuse et la polyarthrite [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":60165,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"cdhf2022_sponsors_meta":[],"footnotes":""},"categories":[111],"tags":[167],"class_list":["post-60175","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-article-fr","tag-biologics-biosimilars-fr"],"acf":{"article_writer":null},"featured_image_src":"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-1.webp","author_info":{"display_name":"Kelsey Cheyne","author_link":"https:\/\/cdhf.ca\/fr\/author\/kelsey-cheyne\/"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>L&#039;\u00e8re \u00e9volutive des biosimilaires - Canadian Digestive Health Foundation<\/title>\n<meta name=\"description\" content=\"D\u00e9couvrez comment les biosimilaires am\u00e9liorent l&#039;acc\u00e8s aux traitements des MICI au Canada et le processus de passage d&#039;un biosimilaire \u00e0 un autre.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L&#039;\u00e8re \u00e9volutive des biosimilaires - Canadian Digestive Health Foundation\" \/>\n<meta property=\"og:description\" content=\"D\u00e9couvrez comment les biosimilaires am\u00e9liorent l&#039;acc\u00e8s aux traitements des MICI au Canada et le processus de passage d&#039;un biosimilaire \u00e0 un autre.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Digestive Health Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CDHFdn\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-10T20:13:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-11T13:15:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Kelsey Cheyne\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TheCDHF\" \/>\n<meta name=\"twitter:site\" content=\"@TheCDHF\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kelsey Cheyne\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/\"},\"author\":{\"name\":\"Kelsey Cheyne\",\"@id\":\"https:\/\/cdhf.ca\/fr\/#\/schema\/person\/990293ff50f898caf38644b75a0105aa\"},\"headline\":\"L&#8217;\u00e8re \u00e9volutive des biosimilaires\",\"datePublished\":\"2025-07-10T20:13:40+00:00\",\"dateModified\":\"2025-07-11T13:15:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/\"},\"wordCount\":1283,\"publisher\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-1.webp\",\"keywords\":[\"Biologics &amp; Biosimilars\"],\"articleSection\":[\"Article\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/\",\"url\":\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/\",\"name\":\"L'\u00e8re \u00e9volutive des biosimilaires - Canadian Digestive Health Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-1.webp\",\"datePublished\":\"2025-07-10T20:13:40+00:00\",\"dateModified\":\"2025-07-11T13:15:58+00:00\",\"description\":\"D\u00e9couvrez comment les biosimilaires am\u00e9liorent l'acc\u00e8s aux traitements des MICI au Canada et le processus de passage d'un biosimilaire \u00e0 un autre.\",\"breadcrumb\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#primaryimage\",\"url\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-1.webp\",\"contentUrl\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-1.webp\",\"width\":2000,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cdhf.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L&#8217;\u00e8re \u00e9volutive des biosimilaires\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cdhf.ca\/fr\/#website\",\"url\":\"https:\/\/cdhf.ca\/fr\/\",\"name\":\"Canadian Digestive Health Foundation\",\"description\":\"Serving Canadians with the latest digestive health news &amp; information\",\"publisher\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cdhf.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cdhf.ca\/fr\/#organization\",\"name\":\"Canadian Digestive Health Foundation\",\"url\":\"https:\/\/cdhf.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/cdhf.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/07\/CDHF_logo_sqstck_4line_CMYK.png\",\"contentUrl\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/07\/CDHF_logo_sqstck_4line_CMYK.png\",\"width\":1154,\"height\":554,\"caption\":\"Canadian Digestive Health Foundation\"},\"image\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/CDHFdn\",\"https:\/\/x.com\/TheCDHF\",\"https:\/\/www.instagram.com\/cdhf_\/?hl=en\",\"https:\/\/www.youtube.com\/user\/CDHFtube\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cdhf.ca\/fr\/#\/schema\/person\/990293ff50f898caf38644b75a0105aa\",\"name\":\"Kelsey Cheyne\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L'\u00e8re \u00e9volutive des biosimilaires - Canadian Digestive Health Foundation","description":"D\u00e9couvrez comment les biosimilaires am\u00e9liorent l'acc\u00e8s aux traitements des MICI au Canada et le processus de passage d'un biosimilaire \u00e0 un autre.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/","og_locale":"fr_FR","og_type":"article","og_title":"L'\u00e8re \u00e9volutive des biosimilaires - Canadian Digestive Health Foundation","og_description":"D\u00e9couvrez comment les biosimilaires am\u00e9liorent l'acc\u00e8s aux traitements des MICI au Canada et le processus de passage d'un biosimilaire \u00e0 un autre.","og_url":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/","og_site_name":"Canadian Digestive Health Foundation","article_publisher":"https:\/\/www.facebook.com\/CDHFdn","article_published_time":"2025-07-10T20:13:40+00:00","article_modified_time":"2025-07-11T13:15:58+00:00","og_image":[{"width":2000,"height":900,"url":"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-1.webp","type":"image\/png"}],"author":"Kelsey Cheyne","twitter_card":"summary_large_image","twitter_creator":"@TheCDHF","twitter_site":"@TheCDHF","twitter_misc":{"Written by":"Kelsey Cheyne","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#article","isPartOf":{"@id":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/"},"author":{"name":"Kelsey Cheyne","@id":"https:\/\/cdhf.ca\/fr\/#\/schema\/person\/990293ff50f898caf38644b75a0105aa"},"headline":"L&#8217;\u00e8re \u00e9volutive des biosimilaires","datePublished":"2025-07-10T20:13:40+00:00","dateModified":"2025-07-11T13:15:58+00:00","mainEntityOfPage":{"@id":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/"},"wordCount":1283,"publisher":{"@id":"https:\/\/cdhf.ca\/fr\/#organization"},"image":{"@id":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#primaryimage"},"thumbnailUrl":"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-1.webp","keywords":["Biologics &amp; Biosimilars"],"articleSection":["Article"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/","url":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/","name":"L'\u00e8re \u00e9volutive des biosimilaires - Canadian Digestive Health Foundation","isPartOf":{"@id":"https:\/\/cdhf.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#primaryimage"},"image":{"@id":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#primaryimage"},"thumbnailUrl":"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-1.webp","datePublished":"2025-07-10T20:13:40+00:00","dateModified":"2025-07-11T13:15:58+00:00","description":"D\u00e9couvrez comment les biosimilaires am\u00e9liorent l'acc\u00e8s aux traitements des MICI au Canada et le processus de passage d'un biosimilaire \u00e0 un autre.","breadcrumb":{"@id":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#primaryimage","url":"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-1.webp","contentUrl":"https:\/\/cdhf.ca\/wp-content\/uploads\/2025\/07\/Copy-of-Banners-for-Website-FOR-UBC-STUDENTS-1.webp","width":2000,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/cdhf.ca\/fr\/lere-evolutive-des-biosimilaires\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cdhf.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"L&#8217;\u00e8re \u00e9volutive des biosimilaires"}]},{"@type":"WebSite","@id":"https:\/\/cdhf.ca\/fr\/#website","url":"https:\/\/cdhf.ca\/fr\/","name":"Canadian Digestive Health Foundation","description":"Serving Canadians with the latest digestive health news &amp; information","publisher":{"@id":"https:\/\/cdhf.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cdhf.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/cdhf.ca\/fr\/#organization","name":"Canadian Digestive Health Foundation","url":"https:\/\/cdhf.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/cdhf.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/07\/CDHF_logo_sqstck_4line_CMYK.png","contentUrl":"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/07\/CDHF_logo_sqstck_4line_CMYK.png","width":1154,"height":554,"caption":"Canadian Digestive Health Foundation"},"image":{"@id":"https:\/\/cdhf.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CDHFdn","https:\/\/x.com\/TheCDHF","https:\/\/www.instagram.com\/cdhf_\/?hl=en","https:\/\/www.youtube.com\/user\/CDHFtube"]},{"@type":"Person","@id":"https:\/\/cdhf.ca\/fr\/#\/schema\/person\/990293ff50f898caf38644b75a0105aa","name":"Kelsey Cheyne"}]}},"_links":{"self":[{"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/posts\/60175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/comments?post=60175"}],"version-history":[{"count":0,"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/posts\/60175\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/media\/60165"}],"wp:attachment":[{"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/media?parent=60175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/categories?post=60175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/tags?post=60175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}